Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLYCD | O95822 | 7/20 | 0.42 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.38 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.38 |
| ▸ | PGR | P06401 | 1/20 | 0.37 |
| ▸ | RORA | P35398 | 1/20 | 0.37 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
| ▸ | RORB | Q92753 | 1/20 | 0.37 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.37 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.36 |
| ▸ | CKS1B | P61024 | 1/20 | 0.36 |
| ▸ | SKP1 | P63208 | 1/20 | 0.36 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4417912 | 0.85 | EGLN1 (0.46) | MLYCDEGLN1PGRRORARORC | |
| SCHEMBL4430547 | 0.84 | MLYCD (0.41) | MLYCDNR1H2NR1H3PGRRORA | |
| SCHEMBL4424179 | 0.79 | MLYCD (0.39) | MLYCDPGRRORARORCRORB | |
| SCHEMBL4420347 | 0.79 | MLYCD (0.41) | MLYCDNR1H2NR1H3CKS1BSKP1 | |
| SCHEMBL4422948 | 0.78 | MLYCD (0.43) | MLYCDNR1H2NR1H3PGRRORA | |
| SCHEMBL4422260 | 0.77 | MLYCD (0.38) | MLYCDCKS1BSKP1SKP2MEN1 | |
| SCHEMBL4424260 | 0.76 | PLAU (0.41) | EGLN1MEN1KMT2A | |
| SCHEMBL4430579 | 0.75 | TRPV4 (0.47) | TRPV4 | |
| SCHEMBL4428901 | 0.74 | MLYCD (0.42) | MLYCDNR1H2NR1H3 | |
| SCHEMBL4430683 | 0.74 | EGLN2 (0.40) | MLYCDNR1H2NR1H3RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080070869-A1 | Malonyl-CoA Decarboxylase Inhibitors Useful as Metabolic Modulators | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2008-03-20 | — | — | US | claimed |
| US-7279477-B2 | Malonyl-CoA decarboxylase inhibitors useful as metabolic modulators | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-10-09 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070869-A1 | Malonyl-CoA Decarboxylase Inhibitors Useful as Metabolic Modulators | MLYCD, ME3, ACACA | MLYCD 1/4885EGLN1 1863/4885NR1H2 1233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.